Apogee Therapeutics (APGE) Status Update summary

Pipeline progress and clinical updates

• APG777 demonstrates a 77-day half-life, supporting every three- to six-month or annual dosing for atopic dermatitis, with phase 2 part A 16-week topline data expected mid-2025 due to accelerated enrollment.

• APG808, an IL-4Rα antibody, shows a 55-day half-life and strong biomarker inhibition, supporting every two- to three-month dosing and a well-tolerated profile, with phase 1b asthma data expected 1H 2025.

• Combination therapies, including APG777 + APG990 and APG777 + APG333, are advancing, with preclinical proof-of-concept, coformulation stability, and broad inhibition of types 1, 2, and 3 inflammation; first combination trial in atopic dermatitis to start in 2025, head-to-head against Dupixent.

• APG777 phase 2 trial tests 30%-40% higher exposures than lebrikizumab or EBGLYSS in induction, aiming for improved efficacy and up to 13-fold fewer injections per year.

• APG777 phase 2 trial in eosinophilic esophagitis is planned for 2026, expanding the pipeline's reach.

Scientific rationale and biomarker strategy

• Higher exposures of APG777 are hypothesized to improve efficacy based on exposure-response data from lebrikizumab and real-world evidence.

• Biomarker analysis shows deep and sustained inhibition of pSTAT6 and TARC, supporting both induction and maintenance efficacy and providing a path to annual dosing.

• Combination of IL-13 and OX40L inhibition aims to achieve JAK-like efficacy without associated safety risks, with selective inhibition of chronic inflammation while preserving antiviral responses.

• Preclinical models demonstrate that APG777 and APG333 together can block both type 2 and non-type 2 inflammation, potentially breaking through the efficacy ceiling seen with monotherapies and improving airway epithelial integrity in COPD models.

• Preclinical data suggest APG777 + APG333 could achieve similar efficacy to lunsekimig with far fewer injections, enhancing patient convenience.

Market opportunity and commercial strategy

• APG777 targets large, underpenetrated markets in atopic dermatitis, asthma, and COPD, with potential to disrupt current treatment paradigms through less frequent dosing and higher efficacy; atopic dermatitis market projected to exceed $50B.

• Market research indicates strong patient, physician, and payer preference for APG777's dosing profile, with 94% of patients and 92% of physicians favoring it over current options if efficacy is maintained; payers indicate support for parity coverage.

• Combination therapies are expected to further raise the efficacy bar and capture additional market share, with a strategy to self-cannibalize and continuously improve offerings.

• Commercial launch plans prioritize APG777 monotherapy, followed by rapid advancement of combination products to maintain leadership and address evolving patient needs.

• Strong financial position with $754M in cash, providing runway into 2028 and supporting multiple near-term clinical catalysts.